Pliant Therapeutics to highlight Phase 2a interim data on bexotegrast

Pliant Therapeutics announced a late-breaking presentation of results from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis at The Liver Meeting 2023 of the American Association for the Study of Liver Diseases, in Boston, Massachusetts, November 10 – 14. Bexotegrast is an oral, small molecule, dual selective inhibitor of alphavss6 and alphavss1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis and PSC. The oral presentation titled “Oral alphavbeta6/alphaVbeta1 Integrin Inhibition in Primary Sclerosing Cholangitis: 12-week Interim Safety and Efficacy Analysis of INTEGRIS-PSC, A Phase 2a Trial of Bexotegrast,” will be delivered by Professor Gideon Hirschfield, M.D., Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Toronto Centre for Liver Disease. “We are pleased to be sharing these positive interim results from the INTEGRIS-PSC trial with the scientific and medical communities as part of this leading hepatology conference,” said Eric Lefebvre, M.D., Chief Medical Officer of Pliant. “Recognizing that no approved treatments are available for patients with PSC, we look forward to the further investigation of bexotegrast including 12 week data from the 320 mg dose in the first quarter of 2024 and 24 week safety data in mid-2024.”